Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NYSE:CPHI NASDAQ:EXOZ NASDAQ:FTLF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.18-1.4%$1.81$1.27▼$4.75$86.02M1.71223,782 shs111,837 shsCPHIChina Pharma$0.55-0.4%$0.60$0.50▼$2.60$22.13M0.9942,767 shs4,788 shsEXOZeXoZymes$9.65-2.5%$8.87$7.08▼$18.40$81.79M2.856,049 shs1,198 shsFTLFFitLife Brands$9.29-1.5%$12.14$8.67▼$20.98$87.19M-0.0123,016 shs33,064 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote+0.91%-1.78%+38.99%-0.45%-32.00%CPHIChina Pharma+1.71%-4.97%-15.08%-25.90%-71.47%EXOZeXoZymes-0.41%-5.18%+11.10%-13.23%-10.51%FTLFFitLife Brands+1.62%+1.84%-11.12%-40.73%-39.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.18-1.4%$1.81$1.27▼$4.75$86.02M1.71223,782 shs111,837 shsCPHIChina Pharma$0.55-0.4%$0.60$0.50▼$2.60$22.13M0.9942,767 shs4,788 shsEXOZeXoZymes$9.65-2.5%$8.87$7.08▼$18.40$81.79M2.856,049 shs1,198 shsFTLFFitLife Brands$9.29-1.5%$12.14$8.67▼$20.98$87.19M-0.0123,016 shs33,064 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote+0.91%-1.78%+38.99%-0.45%-32.00%CPHIChina Pharma+1.71%-4.97%-15.08%-25.90%-71.47%EXOZeXoZymes-0.41%-5.18%+11.10%-13.23%-10.51%FTLFFitLife Brands+1.62%+1.84%-11.12%-40.73%-39.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 2.25Hold$2.7526.26% UpsideCPHIChina Pharma 0.00N/AN/AN/AEXOZeXoZymes 1.00SellN/AN/AFTLFFitLife Brands 2.25Hold$21.50131.56% UpsideCurrent Analyst Ratings BreakdownLatest CPHI, BTMD, EXOZ, and FTLF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2026BTMDbiote Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.004/7/2026FTLFFitLife Brands Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/2/2026FTLFFitLife Brands Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.003/12/2026BTMDbiote National Bank FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$2.503/12/2026BTMDbiote TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.503/12/2026BTMDbiote B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$3.00 ➝ $2.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$192.22M0.45$0.60 per share3.63($1.40) per share-1.56CPHIChina Pharma$4.14M5.38N/AN/A$0.70 per share0.79EXOZeXoZymes$70K1,168.42N/AN/A$0.40 per share24.11FTLFFitLife Brands$81.46M1.07$1.12 per share8.28$4.65 per share2.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$27.05M$0.752.9011.46N/A14.07%-23.41%14.63%5/6/2026 (Estimated)CPHIChina Pharma-$3.08M-$0.75N/AN/AN/A-85.56%-63.93%-31.42%N/AEXOZeXoZymes-$9.16M-$1.08N/AN/AN/AN/A-147.18%-104.98%N/AFTLFFitLife Brands$6.33M$0.6314.657.80N/A7.77%19.75%9.57%N/ALatest CPHI, BTMD, EXOZ, and FTLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026BTMDbiote$0.09N/AN/AN/A$46.02 millionN/A3/30/2026Q4 2025EXOZeXoZymesN/A-$0.31N/A-$0.31N/AN/A3/11/2026Q4 2025BTMDbiote$0.05$0.06+$0.01$0.06$45.79 million$46.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/ACPHIChina PharmaN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.220.79CPHIChina Pharma0.220.790.26EXOZeXoZymes0.022.512.51FTLFFitLife Brands0.881.530.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%CPHIChina PharmaN/AEXOZeXoZymesN/AFTLFFitLife Brands2.32%Insider OwnershipCompanyInsider OwnershipBTMDbiote32.40%CPHIChina Pharma6.40%EXOZeXoZymes72.41%FTLFFitLife Brands61.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19439.55 million26.74 millionNot OptionableCPHIChina Pharma25040.52 million15.92 millionNot OptionableEXOZeXoZymes298.48 million2.34 millionN/AFTLFFitLife Brands209.39 million3.63 millionNot OptionableCPHI, BTMD, EXOZ, and FTLF HeadlinesRecent News About These CompaniesFitLife Brands Announces First Quarter Earnings CallMay 5 at 3:00 PM | globenewswire.comFitLife Will Need To See Real Progress To Remain In Our PortfolioApril 29, 2026 | seekingalpha.comFitLife Brands Inc. (NASDAQ:FTLF) Sees Significant Growth in Short InterestApril 28, 2026 | marketbeat.comBear of the Day: FitLife Brands (FTLF)April 21, 2026 | zacks.comRoth Capital Highlights Discontinued CBD Products Weighing on FitLife Brands, Inc. (FTLF)April 17, 2026 | finance.yahoo.comFitLife Brands Inc. (NASDAQ:FTLF) Sees Large Growth in Short InterestApril 16, 2026 | marketbeat.comFitLife Brands (FTLF) Gets a Buy from Roth MKMApril 16, 2026 | theglobeandmail.com5 Best Beaten Down Stocks to Invest in According to AnalystsApril 16, 2026 | insidermonkey.comFitLife Brands (NASDAQ:FTLF) Director Buys $29,280.00 in StockApril 15, 2026 | insidertrades.comMatthew Lingenbrink Acquires 3,000 Shares of FitLife Brands (NASDAQ:FTLF) StockApril 14, 2026 | marketbeat.comFitLife Brands (NASDAQ:FTLF) Director Grant Robert Dawson Buys 3,000 SharesApril 14, 2026 | marketbeat.comFitLife Brands' Recent Selloff Was Justified (Rating Downgrade)April 10, 2026 | seekingalpha.comFitLife Brands (FTLF) price target decreased by 23.91% to 17.85April 9, 2026 | msn.comZacks Research Downgrades FitLife Brands (NASDAQ:FTLF) to Strong SellApril 9, 2026 | marketbeat.comFitLife Brands Inc (FTLF) Q4 2025 Earnings Call Highlights: Revenue Soars 73% Amid Strategic MovesApril 8, 2026 | finance.yahoo.comFitLife Brands, Inc. (NASDAQ:FTLF) Q4 2025 earnings call transcriptApril 3, 2026 | msn.comFitLife outlines Irwin Amazon run rate of $9M to $10M while holding off on 2026 guidanceApril 2, 2026 | seekingalpha.comFitLife Brands, Inc. (FTLF) Q4 2025 Earnings Call TranscriptApril 2, 2026 | seekingalpha.comFitLife Brands, Inc.: FitLife Brands Announces Fourth Quarter and Full-Year 2025 ResultsApril 2, 2026 | finanznachrichten.deFitLife Brands Announces Fourth Quarter and Full-Year 2025 ResultsApril 1, 2026 | globenewswire.comFitLife Brands Announces Fourth Quarter Earnings CallMarch 30, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPHI, BTMD, EXOZ, and FTLF Company Descriptionsbiote NASDAQ:BTMD$2.18 -0.03 (-1.45%) As of 01:40 PM Eastern This is a fair market value price provided by Massive. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.China Pharma NYSE:CPHI$0.55 0.00 (-0.40%) As of 01:39 PM Eastern This is a fair market value price provided by Massive. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.eXoZymes NASDAQ:EXOZ$9.64 -0.25 (-2.48%) As of 01:38 PM Eastern This is a fair market value price provided by Massive. Learn more.eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.FitLife Brands NASDAQ:FTLF$9.28 -0.15 (-1.54%) As of 01:39 PM Eastern This is a fair market value price provided by Massive. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
